Clinical Trials
10 trialsNCT02588651 2025-11-21
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Case Comprehensive Cancer Center
Phase 2 Completed
NCT03217643 2024-06-20
EATL-001
Imagine Institute
Phase 2 Completed
NCT02561273 2023-12-13
Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
University of Nebraska
Phase 1/2 Completed
NCT03049449 2023-01-18
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02551289 2020-04-21
MARCO
University of Nottingham
Completed
NCT02652715 2019-11-15
Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma
Mayo Clinic
Phase NA Completed
NCT00697346 2019-05-31
Study of MLN8237 in Participants With Advanced Hematological Malignancies
Takeda
Phase 1 Completed
NCT01590732 2018-09-19
Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00787527 2014-09-09
SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00901147 2014-06-27
Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma
Singapore General Hospital
Phase 2 Completed